RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:60% of the road = 270-daysCancerSlayer wrote: I don't see an early JV or buyout happening if TLT is at all interested in maximizing value for themselves or their shareholders. There's just so much additional potential/value post NMIBC approval. Considering we can get to ~$1 US post approval (? on this exchange), it would be a low-risk play imo to dilute by ~15% in order to build cash/R&D/commercial reserves & independently move forward with a Ph 1 NSCLC trial (significantly less costly than a Ph 2) with the strong likelihood of getting further clinical validation of this tech. We would be transforming a single blade pocket knife into a Swiss army...The above funding doesn't take into account the likely grant monies that could follow an NMIBC approval. Throw in any significant progress made on the vaccine front, the total gains made in company value would significantly offset any shareholder losses from dilution. Good luck....
Well Slayer,
It might not happen that early. A JV deal on just NMIBC might be a good deal for TLT. There are other partial deals like that that could bring them some money. They said they have 6 mos of $$ left, Yet I think that is worse case? Assuming they don't get any SP boost for some reasons. All they need is a boost above .50c and Oct warrants should come into play. Lots of options as long as the data comes in as you say. ~ 40% or hopefully better. And I like your idea on the aerosols for their Covid tech...